Dexcom Inc is a leading company specializing in continuous glucose monitoring systems for individuals with diabetes. Their innovative technology enables users to track glucose levels in real time through a small sensor placed under the skin, eliminating the need for traditional fingerstick testing. The company's products empower patients and healthcare providers to make informed decisions regarding diabetes management, enhancing the quality of life for those living with the condition. By integrating advanced software and mobile applications, Dexcom's systems deliver essential insights and alerts, contributing to better health outcomes for users. Read More
Shares of medical device company DexCom (NASDAQ:DXCM)
jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The stock had previously plunged more than 14% after the company's interim CEO stated during its third-quarter earnings call that revenue growth for 2026 could fall short of analyst expectations. This cautious forecast overshadowed an otherwise strong report, in which the company beat third-quarter earnings and revenue estimates. DexCom also raised its full-year 2025 revenue outlook. The sharp drop in previous sessions suggested investors focused more on the future growth warning than the positive current results, and the subsequent modest gain indicated some bargain hunting.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
RADNOR, PA - November 3, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) ( NASDAQ: DXCM ) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025.
Friday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to analysts’ estimates. Its non-GAAP profit of $0.61 per share was 7.5% above analysts’ consensus estimates.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q3 CY2025, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to analysts’ estimates. Its non-GAAP profit of $0.61 per share was 7.5% above analysts’ consensus estimates.
